Antiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides
Pharmaceutics · 30.07.2026 · 18 (8) · 938
DOI: 10.3390/pharmaceutics18080938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.07.2026. Verfasst von Nazita Yousefieh und 5 weiteren Autor:innen. Beteiligte Einrichtung: CONRAD, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences, Old Dominion University, Norfolk, VA 23507, USA. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Matrubials, Matrubials Inc..
Abstract (Originalsprache)
Background
Sexually transmitted infections (STIs) remain a major global health concern, with over one million new curable cases reported daily and limited long-term treatment options. Additionally, there are limited treatment options for women with bacterial vaginosis (BV), a dysbiotic condition predisposing them to STIs. Computationally designed human-milk-inspired antimicrobial peptides (AMPs) are promising candidates for novel antiviral and antibacterial therapies. This study evaluated the cervicovaginal mucosal safety and antiviral activity of three human-milk-inspired AMPs (MAT-006, UCD-MAT-001, and UCD-MAT-002) previously shown to exhibit antimicrobial activity against BV-causing pathogens.
Methods
AMP cytotoxicity and inflammatory responses were assessed in relevant genital tract cell lines and cervicovaginal tissues in vitro. AMP anti-HIV-1 and anti-HSV-2 activities were characterized in female genital tract cell lines, TZM-bl cells and HEC-1-A cells, respectively, and in time-of-addition (pre-, co-, and post-HIV-1 challenge; and post-HSV-2 challenge) experiments. The impact of seminal plasma on AMPs’ activity was also evaluated.
Results
At the concentrations tested, all three AMPs showed minimal cytotoxicity and no pro-inflammatory responses in cellular and ectocervical tissue explant models. In both co- and post-exposure models, all three AMPs inhibited HIV-1 and HSV-2 replication with IC50 values ranging from 0.78 to 7.72 mg/mL. MAT-006 further showed pre-exposure anti-HIV-1 activity after 6 h (IC50 = 1.07 ± 0.515 mg/mL) and 24 h (IC50 = 0.69 ± 0.152 mg/mL) of incubation. Seminal plasma did not significantly impair MAT-006 and UCD-MAT-001 antiviral activity under experimental conditions.
Conclusions
These findings demonstrate the antiviral activity of human-milk-inspired AMPs against HIV-1 and HSV-2 at concentrations that are safe to the cervicovaginal mucosa in vitro, warranting further preclinical evaluation as microbicide candidates with dual antibacterial and antiviral properties.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CONRAD, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences, Old Dominion University, Norfolk, VA 23507, USA.
- Foods for Health Institute, Department of Food Science and Technology, University of California Davis, Davis, CA 95616, USA.
- Matrubials Inc., 630 Pena Drive, Suite 100, Davis, CA 95618, USA.
ORCID-Profile: Louise A Ouattara, Gustavo F Doncel
Förderung
- Matrubials
- Matrubials Inc.
Zitieren
APA
Yousefieh, N., Ouattara, L. A., Bhutta, M., Shah, I. M., Herrera, C., & Doncel, G. F. (2026). Antiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides. Pharmaceutics, 18(8), 938. https://doi.org/10.3390/pharmaceutics18080938
Vancouver
Yousefieh N, Ouattara LA, Bhutta M, Shah IM, Herrera C, Doncel GF. Antiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides. Pharmaceutics. 2026;18(8):938. doi:10.3390/pharmaceutics18080938
BibTeX
@article{Yousefieh2026,
author = {Yousefieh, Nazita and Ouattara, Louise A and Bhutta, Maimoona and Shah, Ishita M and Herrera, Carolina and Doncel, Gustavo F},
title = {Antiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {938},
doi = {10.3390/pharmaceutics18080938}
}
EUVIMED